Cofactor Genomics, Inc.

This study aimed to see if a new lab test could better predict which patients with head and neck cancer would respond to immunotherapy drugs. The test analyzes a piece of the patient's tumor taken before treatment. The trial was withdrawn before any patients were enrolled.